Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revelation BiosciencesREVB +3.20%28 EV-to-EBIT is 0.89 as of Jul. 16, 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 369 Biotechnology companies, Revelation Biosciences ranks better than 78.05% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Revelation Biosciences's Enterprise Value for the quarter that ended in Mar. 2026 was $-8.66 Mil.
Revelation Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Revelation Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revelation Biosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revelation Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Revelation Biosciences's EV-to-EBIT falls into.
Revelation Biosciences's current Enterprise Value is $-8.94 Mil.
Revelation Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences (REVB) has a EV-to-EBIT of 0.89 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Revelation Biosciences and its competitors. According to the industry distribution chart, Revelation Biosciences ranks #81 out of 369 companies in the Biotechnology industry, placing it in the top 22%.
Is Revelation Biosciences' EV-to-EBIT too high?
Revelation Biosciences' current EV-to-EBIT is 0.89. The Biotechnology industry median EV-to-EBIT is 13.95. Revelation Biosciences' value of 0.89 is 93.6% below this industry median. Based on the distribution chart, Revelation Biosciences ranks #81 out of 369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' EV-to-EBIT compare to ARTL and ONCO?
According to the Biotechnology industry distribution chart, Revelation Biosciences ranks #81 out of 369 companies for EV-to-EBIT. This places Revelation Biosciences in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 13.95. Revelation Biosciences' value of 0.89 is 93.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revelation Biosciences's current EV-to-EBIT of 0.89 is 93.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Revelation Biosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revelation Biosciences's current EV-to-EBIT is 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current EV-to-EBIT of 0.89. The current EV-to-EBIT is 0.89 and 93.6% below the Biotechnology industry median of 13.95. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current EV-to-EBIT is 0.89 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score
Get the complete analysis for REVB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVB has been successfully added to your 
